Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2
32
about 6.3 years
13–90
9 sites in CA, CO, NC +5
What this study is about
This trial is testing a treatment called VNX-101 in people with relapsed or refractory CD19-positive blood cancers. The goal is to see if VNX-101 is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dose Level 1, VNX-101
- 2.Take Dose Level 2, VNX-101
- 3.Take Dose Level 3, VNX-101
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Treatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs)
Secondary: Change from baseline in B-cell counts, Proportion/duration of subjects achieving response, progression free survival, and disease free survival.
Oncology